Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CPN1 | P15169 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28418454 | 0.89 | CYP2C19 (0.58) | CYP2C19LMNAMAPK1CYP2D6SRC | |
| SCHEMBL28704099 | 0.86 | CYP2C19 (0.60) | CYP2C19LMNAMAPK1CYP2D6SRC | |
| SCHEMBL29005917 | 0.86 | CYP2C19 (0.54) | CYP2C19LMNAMAPK1CYP2D6EPHX1 | |
| SCHEMBL9268560 | 0.86 | CYP2C19 (0.50) | CYP2C19LMNASRCPOLBCPN1 | |
| SCHEMBL10975636 | 0.84 | CYP2C19 (0.49) | CYP2C19LMNAPOLBCPN1CPB2 | |
| SCHEMBL11546369 | 0.83 | CYP2C19 (0.55) | CYP2C19LMNAMAPK1CYP2D6SRC | |
| SCHEMBL10885586 | 0.83 | CYP2C19 (0.51) | CYP2C19LMNAMAPK1POLBEPHX1 | |
| SCHEMBL10444607 | 0.82 | CYP2C19 (0.47) | CYP2C19TBXAS1SMN1; SMN2KDM4E | |
| SCHEMBL28857969 | 0.82 | CYP2C19 (0.47) | CYP2C19CPN1CPB2KDM4EALDH1A1 | |
| SCHEMBL27264696 | 0.82 | CYP2C19 (0.47) | CYP2C19LMNAMAPK1CPN1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11604185-B2 | Methods for detection of botulinum neurotoxin | CITY OF HOPE (US) | 2023-03-14 | — | — | US | disclosed |
| US-20210255174-A1 | METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN | CITY OF HOPE (US) | 2021-08-19 | — | — | US | disclosed |
| US-10775366-B2 | Substrates for detection of botulinum neurotoxin | CITY OF HOPE (US) | 2020-09-15 | — | — | US | disclosed |
| EP-3215141-A2 | IMMUNOREGULATORY AGENTS | Flexus Biosciences, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170153228-A1 | METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-01 | — | — | US | disclosed |
| WO-2016073738-A2 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-8753831-B2 | Methods for detection of botulinum neurotoxin | CITY OF HOPE (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130065259-A1 | METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN | CITY OF HOPE (US) | 2013-03-14 | — | — | US | disclosed |
| US-20120322081-A1 | METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-12-20 | — | — | US | disclosed |
| US-8067192-B2 | Methods for detection of botulinum neurotoxin | CITY OF HOPE (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090176259-A1 | METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-09 | — | — | US | disclosed |
| US-4294905-A | DIAZO COMPOUNDS, OLEOPHILIC AND STORAGE STABLE | FUJI PHOTO FILM CO., LTD. (JP) | 1981-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11604185-B2 | Methods for detection of botulinum neurotoxin | ANTXR2, INHA, PRSS12 | CYP2C19 4166/4885LMNA 525/4885MAPK1 4703/4885 |
| US-20210255174-A1 | METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN | ANTXR2, INHA, PRSS12 | CYP2C19 4166/4885LMNA 525/4885MAPK1 4703/4885 |
| US-10775366-B2 | Substrates for detection of botulinum neurotoxin | ANTXR2, INHA, PRSS12 | CYP2C19 4160/4885LMNA 608/4885MAPK1 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.